Last, our findings have implications for the use of MT stabilizing drugs, such as taxol and its derivatives, in the treatment of human cancers, many of which acquire resistance by modulating MCAK activity (Ganguly et al., 2011a; Ganguly et al., 2011b). This evidence concerns the gene KIF2C and cancer.